Evoke Pharma Granted FDA Market Exclusivity for GIMOTI®
26 avr. 2022 08h30 HE
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases,...
Evoke Pharma Announces Approval of GIMOTI® to the Texas Medicaid Preferred Drug List
19 avr. 2022 08h30 HE
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases,...
Evoke Pharma Announces Key Opinion Leader Fireside Chat to Discuss Gastroparesis Treatment Landscape
10 mars 2022 08h30 HE
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases,...
Evoke Pharma Reports Fourth Quarter and Full Year 2021 Financial Results
08 mars 2022 16h05 HE
|
Evoke Pharma, Inc.
Fourth-quarter net product sales from prescriptions increased by 46% to $361,000 versus Q3 Easing of COVID-19 restrictions helped fuel higher sales, increased face-to-face meetings with healthcare...
Evoke Pharma to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022
01 mars 2022 08h30 HE
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
Evoke Pharma and EVERSANA Announce Acceptance of Abstract for Poster of Distinction Presentation at Digestive Disease Week (DDW) May 2022
24 févr. 2022 08h30 HE
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., and CHICAGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal...
GIMOTI® Commercialization Update
17 févr. 2022 08h30 HE
|
Evoke Pharma, Inc.
New Research Study Demonstrates Increased Acceptance Among Healthcare Providers Patient Testimonial Videos Detail Benefits Included and Available on GimotiRx.com Expanded Coverage with recent...
Evoke Pharma and EVERSANA Extend Commercialization Partnership to Further Support GIMOTI
02 févr. 2022 08h30 HE
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif. and CHICAGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company primarily focused on treatments for gastrointestinal (GI)...
Evoke Pharma to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference
04 janv. 2022 08h30 HE
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (G.I.) diseases,...
RPAR Risk Parity ETF, Another Tidal Successful Launch, Surpasses $1.5 Billion AUM
06 déc. 2021 08h00 HE
|
Tidal ETF Services
CHICAGO and MILWAUKEE and NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Tidal ETF Services LLC (“Tidal”), an innovative leading provider of ETF services, announced today the RPAR Risk Parity ETF...